Harmony Biosciences to Release Q2 2025 Financial Results on August 5, 2025, Before Market Open

Harmony Biosciences Holdings Inc (HRMY) will release its Q2 2025 financial results on August 5, 2025, before the U.S. financial markets open. The company will also host a conference call and webcast to discuss the results. The focus on rare neurological diseases positions Harmony Biosciences in a niche market with significant growth potential, but the lack of preliminary data or insights into the company's performance may leave some investors seeking more information.

Harmony Biosciences Holdings Inc (HRMY) will release its Q2 2025 financial results on August 5, 2025, before the U.S. financial markets open. The company will also host a conference call and webcast to discuss the results. This announcement follows the company's Q1 2025 results, which highlighted a 20% year-over-year increase in net product revenue for WAKIX, reaching $184.7 million [4].

Harmony Biosciences is a U.S. commercial-stage pharmaceutical company dedicated to developing and commercializing innovative therapies for people living with rare neurological disorders who have unmet medical needs. The company's focus on rare neurological diseases positions it in a niche market with significant growth potential. However, the lack of preliminary data or insights into the company's performance may leave some investors seeking more information.

The company's Q2 2025 financial results will be closely watched by investors and financial professionals. Harmony Biosciences has a robust late-stage pipeline with 8 assets across 13 development programs, aiming for multiple new product or indication launches each year. The company's strong balance sheet, with over $600 million in cash and cash equivalents, provides flexibility for further pipeline development [4].

Harmony Biosciences' management team will participate in the virtual H.C. Wainwright "HCW@Home" series on Thursday, July 17, 2025, at 10:00 a.m. ET, where they will discuss the company's pipeline and growth prospects [3]. Additionally, the company has announced a settlement agreement with Lupin Limited, resolving the patent infringement litigation related to Lupin’s Abbreviated New Drug Application (ANDA) for a generic version of WAKIX [3].

Investors interested in Harmony Biosciences' Q2 2025 financial results can participate in the conference call and webcast by dialing 833-316-2483 (domestic) or 785-838-9284 (international), and referencing passcode HRMYQ225. The live and replay webcast of the call will be available on the investor page of the company's website at https://ir.harmonybiosciences.com/ [1][2].

References:
[1] https://www.biospace.com/press-releases/harmony-biosciences-to-report-second-quarter-2025-financial-results-on-august-5-2025
[2] https://www.morningstar.com/news/business-wire/20250722796867/harmony-biosciences-to-report-second-quarter-2025-financial-results-on-august-5-2025
[3] https://ir.harmonybiosciences.com/
[4] https://www.gurufocus.com/news/2989460/truist-initiates-buy-rating-for-harmony-biosciences-hrmy-with-promising-growth-prospects-hrmy-stock-news